98%
921
2 minutes
20
Protein arginine N-methyltransferase 5 (PRMT5) has been identified as a potential therapeutic target for various cancer types. However, its role in regulating the hepatocellular carcinoma (HCC) transcriptome remains poorly understood. In this study, publicly available databases were employed to investigate PRMT5 expression, its correlation with overall survival, targeted pathways, and genes of interest in HCC. Additionally, we utilized in-house generated NGS data to explore expression in dysplastic nodules compared to hepatocellular carcinoma. Our findings revealed that PRMT5 is significantly overexpressed in HCC compared to normal liver, and elevated expression correlates with poor overall survival. To gain insights into the mechanism driving overexpression in HCC, we analyzed promoter CpG islands and methylation status in HCC compared to normal tissues. Pathway analysis of knockdown in the HCC cells revealed a connection between expression and genes related to the HIF1α pathway. Additionally, by filtering PRMT5-correlated genes within the HIF1α pathway and selecting up/downregulated genes in HCC patients, we identified Ras-related nuclear protein (RAN) as a target associated with overall survival. For the first time, we report that PRMT5 is implicated in the regulation of and genes, suggesting the potential prognostic utility of PRMT5 in HCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11048327 | PMC |
http://dx.doi.org/10.3390/biology13040216 | DOI Listing |
J Cancer Res Clin Oncol
September 2025
Department of Radiology, Guizhou Provincial People's Hospital, No. 83 East Zhongshan Road, Guiyang, 550002, Guizhou, China.
Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.
Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).
Intern Med
September 2025
Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Japan.
Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.
View Article and Find Full Text PDFNihon Shokakibyo Gakkai Zasshi
January 2025
Department of Surgery, Graduate School of Medicine, Kyoto University.
Gut
September 2025
Curtin Medical School, Curtin University, Bentley, Western Australia, Australia
BMJ Open
September 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.
Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.
View Article and Find Full Text PDF